All News

The first patient has received treatment with mavrostobart plus chemo in the phase 1/2 MORNINGSTAR trial for advanced solid tumors, including lung cancer.

Dr. Tiziano Barbui explains how excess blood cell production in certain myeloproliferative neoplasms can impair circulation and why treatments like phlebotomy are used.

After being diagnosed with breast cancer at 39, I learned to advocate for myself, transforming fear into fierce resolve and purpose through every step.

I reflect on my journey from caregiver to advocate, embracing a future shaped by cancer but no longer defined by it.

Dr. Andrew M. Evens discusses long-term survivorship challenges that can occur among adolescent and young lymphoma survivors.

IDH inhibitors, now FDA approved for lower-grade gliomas, yield fewer side effects than chemotherapy, said Dr. Ryan Merrell.

Maria, my oncology nurse, inspired lasting change in my life through compassion, wisdom and faith during my cancer surgery and recovery.

Kathleen Shuey, M.S., RN, SCON, ACNS-BC, listens and guides us in the right direction in caring for our oncology population.

Fifteen years after being diagnosed with small lymphocytic lymphoma, I’ve found healing and meaning in the work I love and the life I’m grateful to live.

Dr. Andrew M. Evens discusses some of the recent research advancements in AYA lymphoma care that have emerged through clinical trials and initiatives.

After my breast cancer treatment, I started a clothing bank to give others free access to recovery items like post-surgery shirts and pillows.

I urge researchers to look into why side effects occur in cancer drugs and to find ways to mitigate them that doesn’t impact their efficacy.

GLP-1 drugs lowered rates of obesity-related cancers and death versus DPP-4s, with no increased cancer risk, study finds.

Dr. Andrew M. Evens discussed the importance of differentiating AYA cancers from other age groups, specifically focusing on lymphoma care.

Itovebi plus Ibrance and Faslodex improved overall survival in patients with PIK3CA-mutant, HR+, HER2–, endocrine-resistant breast cancer versus placebo.

Among patients with ES-SCLC, first-line maintenance therapy with Zepzelca plus Tecentriq led to improvements in PFS and OS versus Tecentriq alone.

Avoiding smoking, eating a high-fiber diet and routine screenings are key to reducing the risk of recurrence in colorectal or anal cancer.

When I saw a study about using AI facial recognition in cancer decision-making headlines, I decided to try my own informal, non-scientific experiment.

The FDA’s ODAC has voted against the risk/benefit profile of two targeted therapies for the treatment of bladder and prostate cancer, respectively.

A patient with relapsed follicular lymphoma achieved complete remission one month after PMB-CT01 treatment in the phase 1 PMB-102 trial.

DPOAE testing showed no hearing loss in children with retinoblastoma treated with intra-arterial paraplatin, suggesting preserved cochlear function.

Gayle S. Jameson, M.S.N, ACNP-BC, AOCN, is a trailblazer whose expertise and compassion have made a profound impact on oncology care.

JAK inhibitors ease symptoms in myelofibrosis, but only stem cell transplant offers a cure; newer drugs aim to fill unmet needs, especially for anemia.

Dr. Shirley D’Sa discusses how treatment strategies for WM have evolved over the course of her career.

I'm a follicular lymphoma survivor, and hearing others name the quiet, lasting changes of life after cancer made me feel seen and understood.

The FDA'S ODAC has casted their votes on the use of certain treatments in both the relapsed/refractory DLBCL and myeloma patient populations, respectively.

ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage in most patients treated.

I’ve lived with large granular lymphocytic leukemia for 16 years and have learned to spend my energy wisely, embrace palliative care and choose joy over anger.